Gilead's FDA-approved Bixlenvo (BIC/LEN), a grain-of-rice-sized once-daily HIV pill, targets virologically suppressed patients & those with NRTI resistance.
August 27, 2026 06:14 PM EDT
PharmaFDA+
Gilead gets another HIV treatment approval, extending lenacapavir's dominance
Kyle LaHucik
Biotech Correspondent
Bixlenvo combines two existing Gilead drugs into a single tablet for adults whose virus is suppressed but who can't use current…
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV,…
Some 20 years after helping introduce the first once-daily single tablet HIV regimen, Gilead Sciences has crossed the regulatory…
The FDA has approved Bixlenvo, the first single-pill daily HIV therapy for adults being successfully treated on more complex…
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a…
Combo could offer an alternative for those who can't take existing single-tablet regimens
